KNSA Kiniksa Pharmaceuticals Ltd.

15.45
-0.17  -1%
Previous Close 15.62
Open 15.7
Price To Book 3.37
Market Cap 847,916,703
Shares 54,881,340
Volume 451,621
Short Ratio
Av. Daily Volume 282,726
Stock charts supplied by TradingView

NewsSee all news

  1. Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts

    - Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 -- Enrollment target achieved for mavrilimumab Phase 2 trial in giant cell arteritis; top-line data

  2. Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

    SANTA MONICA, Calif. and HAMILTON, Bermuda, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Kite, a Gilead Company (NASDAQ:GILD), and Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa") announced today that the companies have

  3. Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

    -- Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta -- Kite, a Gilead Company (NASDAQ:GILD), and Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa") announced today that the

  4. Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

    HAMILTON, Bermuda, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the

  5. Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

    HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2H 2020.
Rilonacept (RHAPSODY)
Pericarditis
Phase 2 data due 2H 2020.
Mavrilimumab
Giant cell arteritis (GCA)
Phase 1b data showed no meaningful benefit - August 12, 2019.
KPL-716
Atopic dermatitis
Phase 2 data due 1H 2020.
KPL-716
Prurigo nodularis
Phase 2 interim data due 1H 2020.
KPL-716
Chronic Pruritus
Phase 2 trial to be initiated.
Mavrilimumab and Yescarta
Relapsed or Refractory Large B-Cell Lymphoma
Phase 1 data due 2H 2020.
KPL-404
Healthy volunteers

Latest News

  1. Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts

    - Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 -- Enrollment target achieved for mavrilimumab Phase 2 trial in giant cell arteritis; top-line data

  2. Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

    SANTA MONICA, Calif. and HAMILTON, Bermuda, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Kite, a Gilead Company (NASDAQ:GILD), and Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa") announced today that the companies have

  3. Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

    -- Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta -- Kite, a Gilead Company (NASDAQ:GILD), and Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa") announced today that the

  4. Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

    HAMILTON, Bermuda, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the

  5. Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

    HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th,

  6. Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis

    HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic

  7. Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

    - Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores -- Tapering and discontinuation of corticosteroids without pericarditis recurrence - - Markedly lower annualized

  8. Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting

    - Mavrilimumab suppresses pathogenic immune responses in a validated in vivo model of medium and large vessel vasculitis - - Additional human ex vivo data support rationale for targeting GM-CSF in GCA - HAMILTON,

  9. Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

    – Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 –– Operating plan funded into 2H 2021; no current plan to raise additional capital prior to delivering clinical data

  10. Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research

    HAMILTON, Bermuda, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic